Korea is gaining momentum in the First-in-Human Clinical Trial market thanks to its highly digitized healthcare system, strong government funding, and a reputation for regulatory efficiency through the Ministry of Food and Drug Safety (MFDS). The country's centralized infrastructure allows for quick site initiation and high data reliability. With a focus on advanced therapeutics such as stem cells, gene editing, and immunotherapies, South Korea offers a favorable environment for FIH research. However, the relatively small population and limited diversity can restrict broader trial applications. Trends point toward increasing use of virtual trial tools, electronic medical records (EMR) integration, and data analytics to enhance trial quality. With growing collaboration between academia and industry, South Korea presents strong opportunities for innovative, tech-enabled FIH trials.
TABLE - Korea First-in-Human Clinical Trial Market Size & Forecast By Phase Type 2021-2033
Phase Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Phase 0 (Microdosing) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Phase I (FIH Safety/Tolerability) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Korea First-in-Human Clinical Trial Market Size & Forecast By Therapeutic Area 2021-2033
Therapeutic Area | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oncology | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Neurology | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Rare and Orphan Diseases | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Immunology & Infectious Diseases | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Korea First-in-Human Clinical Trial Market Size & Forecast By Sponsor Type 2021-2033
Sponsor Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Companies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Biotech Firms | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Academic/Governmental Institutes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis